SI1545587T1 - Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede - Google Patents

Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede

Info

Publication number
SI1545587T1
SI1545587T1 SI200331990T SI200331990T SI1545587T1 SI 1545587 T1 SI1545587 T1 SI 1545587T1 SI 200331990 T SI200331990 T SI 200331990T SI 200331990 T SI200331990 T SI 200331990T SI 1545587 T1 SI1545587 T1 SI 1545587T1
Authority
SI
Slovenia
Prior art keywords
methods
diabetic ulcer
ulcer treatment
lactoferrin compositions
lactoferrin
Prior art date
Application number
SI200331990T
Other languages
English (en)
Inventor
Jose Engelmayer
Atul Varadhachary
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of SI1545587T1 publication Critical patent/SI1545587T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
SI200331990T 2002-09-16 2003-09-16 Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede SI1545587T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41098102P 2002-09-16 2002-09-16
PCT/US2003/029069 WO2004024180A1 (en) 2002-09-16 2003-09-16 Lactoferrin compositions and methods of wound treatment
EP03752398A EP1545587B1 (en) 2002-09-16 2003-09-16 Lactoferrin compositions and methods of diabetic ulcer treatment

Publications (1)

Publication Number Publication Date
SI1545587T1 true SI1545587T1 (sl) 2011-06-30

Family

ID=31994228

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200331990T SI1545587T1 (sl) 2002-09-16 2003-09-16 Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
SI200332199T SI2298338T1 (sl) 2002-09-16 2003-09-16 Laktoferinski sestavki in postopki za zdravljenjekožnih ran

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200332199T SI2298338T1 (sl) 2002-09-16 2003-09-16 Laktoferinski sestavki in postopki za zdravljenjekožnih ran

Country Status (12)

Country Link
US (3) US7524814B2 (sl)
EP (2) EP1545587B1 (sl)
JP (1) JP4516844B2 (sl)
CN (1) CN1694720A (sl)
AT (1) ATE497778T1 (sl)
AU (2) AU2003270690B2 (sl)
CA (1) CA2499014A1 (sl)
DE (1) DE60335997D1 (sl)
DK (2) DK1545587T3 (sl)
ES (1) ES2358645T3 (sl)
SI (2) SI1545587T1 (sl)
WO (1) WO2004024180A1 (sl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
WO2003099323A1 (en) 2002-05-10 2003-12-04 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) * 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK1545587T3 (da) * 2002-09-16 2011-05-09 Agennix Inc Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
EP1581243A4 (en) * 2002-12-06 2008-01-02 Agennix Inc ORAL LACTOFERRINE FOR THE TREATMENT OF SEPSIES
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2005046571A2 (en) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
DE602005013542D1 (de) * 2004-08-20 2009-05-07 Smithkline Beecham Corp Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US8263105B2 (en) * 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
ITRM20040638A1 (it) 2004-12-24 2005-03-24 Advance Holdings Ltd Gel piastrinico semisintetico e metodo per la sua preparazione.
US20060240116A1 (en) * 2005-04-22 2006-10-26 David Jolley Bioactive factors in wound healing topical compositions and methods
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
US20070059300A1 (en) * 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
US20070116750A1 (en) * 2005-11-18 2007-05-24 Randall Wolcott Compositions for disrupting and inhibiting reconstitution of wound biofilm
US20070179084A1 (en) * 2006-01-30 2007-08-02 Nation Chiao Tung University Process for reducing the concentration of blood glucose in a diabetic patient
ATE449617T1 (de) * 2006-02-02 2009-12-15 Euro Celtique Sa Hydrogel für wundbehandlung
WO2007100555A2 (en) * 2006-02-21 2007-09-07 Ventria Bioscience Compositions containing lactoferrin, and methods of using same to promote growth of skin cells
ES2704454T3 (es) * 2006-07-03 2019-03-18 Perraudin Jean Paul Composiciones antimicrobianas que comprenden hipohalito y/o hipotiocianito y sus usos
GB0616580D0 (en) * 2006-08-21 2006-09-27 Novathera Ltd Composite material
AU2007294808A1 (en) * 2006-09-13 2008-03-20 Southeastern Medical Technologies, Llc Methods and compositions for sealing and adhering biological tissues and medical uses thereof
US10143694B2 (en) * 2006-10-27 2018-12-04 Matthew H. Kopacki Advanced formulations and therapies for treating hard-to-heal wounds
PE20090190A1 (es) * 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
WO2009123720A2 (en) * 2008-04-01 2009-10-08 Southeastern Medical Technologies, Llc Methods and compositions for medical articles produced from proteinaceous compounds
EP2141242A1 (en) * 2008-07-04 2010-01-06 Universität des Saarlandes Synthetic pathway enzymes for the production of Argyrins
US8614189B2 (en) * 2008-09-24 2013-12-24 University Of Connecticut Carbon nanotube composite scaffolds for bone tissue engineering
US20110015587A1 (en) * 2009-07-14 2011-01-20 Tumey David M Irrigation Device and Method Using Same
JP2011020973A (ja) * 2009-07-17 2011-02-03 Nrl Pharma Inc 難治性の皮膚潰瘍治療用の医薬組成物、及び、皮膚潰瘍予防用化粧料
AU2010324979B2 (en) * 2009-11-25 2014-09-25 Nestec S.A. Nutritional compositions including a high protein component and exogenous nucleotides
US8545927B2 (en) 2010-05-10 2013-10-01 University Of Connecticut Lactoferrin-based biomaterials for tissue regeneration and drug delivery
US20130101575A1 (en) * 2010-07-01 2013-04-25 Brien Holden Vision Institute Lactoferrin seqences, compositions and methods for corneal wound treatment
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
US20120171231A1 (en) * 2010-12-29 2012-07-05 Anja Wittke Use of nutritional compositions including lactoferrin in stimulating immune cells
MY162943A (en) * 2011-01-26 2017-07-31 Megmilk Snow Brand Co Ltd Sense-improving agent
WO2012106364A1 (en) * 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
EP2957304B1 (en) * 2011-08-31 2017-02-15 KCI Licensing, Inc. Reduced-pressure treatment and debridement systems and methods
CN104884079B (zh) 2012-11-14 2021-02-12 史密夫和内修公司 稳定的嗜热菌蛋白酶水凝胶
KR20150127280A (ko) 2013-03-15 2015-11-16 스미스 앤드 네퓨, 인크. 활성제의 전달을 위한 용해가능한 겔-형성 필름
JP6275955B2 (ja) * 2013-04-25 2018-02-07 松尾 敏郎 塩化マグネシウムを摂取する人を除いた生物の細胞の活性化方法
CZ308554B6 (cs) * 2013-10-21 2020-11-25 Univerzita Tomáše Bati ve Zlíně Hydrogelová kosmetická nebo farmaceutická kompozice s účinnějším působením v ní obsažených biologicky aktivních látek z hlediska antimikrobiálních účinků
US20170304409A1 (en) 2014-09-24 2017-10-26 ISTITUTO PROFILATTICO E FARMACEUTICO CANDIOLI & C. SPA in abbreviated form CANDIOLI FARMACEUTICI Compositions useful for the prevention and/or treatment of infections and inflammations
RU2658707C1 (ru) * 2016-12-28 2018-06-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ восстановления кожного покрова
US20200024329A1 (en) * 2018-07-17 2020-01-23 Bradley G. Thompson Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
EP3845218A4 (en) * 2018-07-31 2022-05-04 Lemonex Inc. PHARMACEUTICAL COMPOSITION FOR WOUND HEALING
WO2020121179A1 (en) * 2018-12-11 2020-06-18 Universita' Degli Studi Di Salerno Composition for the treatment of skin lesions
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
BE1027357B1 (nl) * 2019-06-12 2021-01-18 Vanlommel Maria Kristel Voedingssupplement voor versnelde genezing
CN110680949B (zh) * 2019-10-18 2021-06-29 中山大学 一种基于母乳的创伤敷料的制备方法和应用
CA3229789A1 (en) * 2021-08-23 2023-03-02 Lactea Therapeutics Llc Lactoferrin compositions and methods of use
CN113576938B (zh) * 2021-08-26 2022-07-08 广东丸美生物技术股份有限公司 一种口腔护理组合物及其应用
CN116421775A (zh) * 2023-04-21 2023-07-14 青岛优瑞达生物科技有限公司 一种乳铁蛋白凝胶敷料、制备方法和应用
CN116251224B (zh) * 2023-05-16 2023-09-12 江苏正大天创生物工程有限公司 一种乳铁蛋白凝胶敷料及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4788488A (en) * 1986-10-14 1988-11-29 Drexelbrook Controls, Inc. Continuous condition sensing system
US4783488A (en) * 1987-01-31 1988-11-08 Bausch & Lomb Incorporated Contact lens wetting solution
US4977137B1 (en) 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5849881A (en) 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5766939A (en) 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5198419A (en) 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
DE69033606T2 (de) * 1990-01-12 2001-04-26 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Verfahren zur verbesserung der wundheilung und gewebeerneuerung
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
GB2248842A (en) 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
EP0579830B1 (en) * 1990-11-13 1997-02-05 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal lesion
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
WO1993013216A1 (en) 1991-12-24 1993-07-08 The President And Fellows Of Harvard College Site-directed mutagenesis of dna
EP0559425B1 (en) * 1992-03-02 1999-01-07 Immuno Japan Inc. Use of proteins belonging to the transferrin/lactoferrin family for potentiating the immune system
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
DE4294862T1 (de) * 1992-04-10 1994-06-09 Vni Skij I Medicinskich Polime Pharmazeutische Komposition
ZA932568B (en) 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5358706A (en) 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
JPH07196529A (ja) * 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd 創傷治癒剤、化粧料および養毛剤
DE69524386D1 (de) 1994-02-16 2002-01-17 Pharming Intellectual Pty Bv Isolierung von lactoferrin aus milch
JP3746081B2 (ja) 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
US5827874A (en) 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US6111081A (en) 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
GB2321191B (en) * 1997-01-17 2000-09-27 Johnson & Johnson Medical Peptides for use in wound treatment
US6333311B1 (en) 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof
ATE297755T1 (de) 1997-04-10 2005-07-15 Agennix Inc Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
JP3856908B2 (ja) * 1997-06-06 2006-12-13 田辺製薬株式会社 褥瘡及び／又は創傷治療剤
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
EP1404412B1 (en) 2001-06-13 2012-03-21 The University of Sydney Protein C for wound healing
WO2003099323A1 (en) 2002-05-10 2003-12-04 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK1545587T3 (da) * 2002-09-16 2011-05-09 Agennix Inc Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
US7026295B2 (en) 2002-12-04 2006-04-11 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
EP1581243A4 (en) 2002-12-06 2008-01-02 Agennix Inc ORAL LACTOFERRINE FOR THE TREATMENT OF SEPSIES
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
US7034126B2 (en) 2003-05-14 2006-04-25 Agennix, Inc. Lactoferrin in the treatment of diabetes mellitus
WO2005046571A2 (en) 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Also Published As

Publication number Publication date
EP1545587A1 (en) 2005-06-29
DK1545587T3 (da) 2011-05-09
ES2358645T3 (es) 2011-05-12
CA2499014A1 (en) 2004-03-25
JP4516844B2 (ja) 2010-08-04
EP2298338B1 (en) 2012-08-22
US20120010150A1 (en) 2012-01-12
EP1545587A4 (en) 2009-06-17
AU2009225309A1 (en) 2009-11-05
DE60335997D1 (de) 2011-03-24
JP2006503044A (ja) 2006-01-26
DK2298338T3 (da) 2012-09-24
AU2003270690B2 (en) 2009-07-30
CN1694720A (zh) 2005-11-09
AU2009225309B2 (en) 2012-06-14
US7524814B2 (en) 2009-04-28
EP2298338A1 (en) 2011-03-23
US20090253627A1 (en) 2009-10-08
US8247373B2 (en) 2012-08-21
SI2298338T1 (sl) 2012-11-30
AU2003270690A1 (en) 2004-04-30
US8030272B2 (en) 2011-10-04
EP1545587B1 (en) 2011-02-09
ATE497778T1 (de) 2011-02-15
WO2004024180A1 (en) 2004-03-25
US20040142037A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
SI1545587T1 (sl) Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
HK1145692A1 (zh) 人血管生成素- 的特異結合劑
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
HK1158493A1 (en) Hair treatment agent composition and method for production thereof
AU2003274941A1 (en) A method of treating human skin and a skin care composition for use in such a method
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
HK1071525A1 (en) Method and composition for treating skin wounds with epidermal growth factor
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
EP1549324A4 (en) COMPOSITION AND METHOD FOR BRIGHTENING SKIN
IL161073A0 (en) Composition and method for treating diabetes
EP1648399A4 (en) METHOD AND TOPIC COMPOSITION FOR TREATING SKIN HYPERPIGMENTATION
GB2411356B (en) Compositions useful in treating affective, painful or allergic disorders
GB2399500B (en) Composition and method for treatment of wounds
AU2003275433A8 (en) Compositions and methods for treating pain
GB2401044B (en) A composition for use in the treatment or prophylaxis of a skin condition in a subject
AU2003291461A8 (en) Compositions for diabetes treatment and prophylaxis
IL164536A0 (en) The use of hydroxypyridone-derivatives in wound healing
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
UA6151U (en) Method for treating experimental burns
AU2003251300A1 (en) Composition and method for the treatment of personal odors
ZA200306400B (en) Method of and composition for use in treating eggs.
UA32384A (uk) Спосіб лікування пародонтиту